Understanding comorbid depression and anxiety

Psychiatric Times

Volumn 24, Issue 14, 2007, Pages 51-56

  Cameron, Oliver G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38049135164     PISSN: 08932905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617-627.
2. Kaufman J, Charney D. Comorbidity of mood and anxiety disorders. Depress Anxiety. 2000;12:69-76.
3. Gorman JM. Comorbid depression and anxiety spectrum disorders. Depress Anxiety. 1996/7;4:160-168.
4. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593-602.
5. Prince M, Patel V, Saxena S, et al. No health without mental health. Lancet. 2007;370:859-877.
6. Pollack MH. Comorbid anxiety and depression. J Clin Psychiatry. 2005;66:22-29.
7. Kendler KS, Neale MD, Kessler RC, et al. Major depression and generalized anxiety disorder: (partly) different environments? Arch Gen Psychiatry. 1992;48:716-722.
8. Weissman MM. Family genetic studies of panic disorder. J Psychiatr Res. 1993;27(suppl 1):69-78.
9. Kendler KS, Walters EE, Neale MC, et al. The structure of the genetic and environmental risk factors for six major psychiatric disorders in women: phobia, generalized anxiety disorder, panic disorder, bulimia, major depression, and alcoholism. Arch Gen Psychiatry. 1995;52:374-383.
10. Wittchen HU, Kessler RC, Pfister RC, Lieb M. Why do people with anxiety disorders become depressed? A prospective-longitudinal community study. Acta Psychiatr Scand. 2000;406:14-23.
11. Roy-Byrne PP, Stang P, Wittchen HU, et al. Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course, and help-seeking. Br J Psychiatry. 2000;176:229-235.
12. Belzer K, Schneier FR. Comorbidity of anxiety and depressive disorders: issues of conceptualization, assessment, and treatment. J Psychiatr Pract. 2004;10:296-306.
13. Cameron OG. Anxious-depressive comorbidity: effects on HPA axis and CNS noradrenergic functions. Essent Psychopharmacol. 2006;7:24-34.
14. Finley-Jones R, Brown GW. Types of stressful life event and the onset of anxiety and depressive disorders. Psychol Med. 1981;11:803-815.
15. Baldwin DS, Evans DL, Hirschfeld RM, Kasper S. Can we distinguish anxiety from depression? Psychopharmacol Bull. 2002;36(suppl 2):158-165.
16. Young EA, Abelson JL, Cameron OG. Effect of comorbid anxiety disorders on the hypothalamic-pituitary-adrenal axis response to a social stressor in major depression. Biol Psychiatry. 2004;56:113-120.
17. Cameron OG, Abelson JL, Young EA. Anxious and depressive disorders and their comorbidity: effect on central nervous system noradrenergic function. Biol Psychiatry. 2004;56:875-883.
18. Young EA, Abelson JL, Cameron OG. Interaction of brain noradrenergic system and the hypothalamic-pituitary adrenal (HPA) axis in man. Psychoneuroendocrinology. 2005;30:807-814.
19. Boerner RJ, Moller HJ. The importance of new antidepressants in the treatment of anxiety/depressive disorders. Pharmacopsychiatry. 1999;32:119-126.
20. Borkovec TD, Ruscio AM. Psychotherapy for generalized anxiety disorder. J Clin Psychiatry. 2001;62:37-42.
21. Kapczinski F, Lima MS, Souza JS, et al. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev. 2003;(2):CD003592..
22. Panzer MJ. Are SSRIs really more effective for anxious depression? Ann Clin Psychiatry. 2005;17:23-29.
23. Furukawa TA, Streiner DL, Young LT, Konoshita Y. Antidepressants plus benzodiazepines for major depression. Cochrane Database Syst Rev. 2001;(3):CD001026.
24. Grunhaus L, Harel Y, Krugler T, et al. Major depressive order and panic disorder. Effects of comorbidity on treatment outcome with antidepressant medications. Clin Neuropharmacol. 1988;11:454-461.
25. Tollefson GD, Greist JH, Jefferson JW, et al. Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor? A comparative trial of fluoxetine versus Imipramine. J Clin Psychopharmacol. 1994;14:385-391.
26. Pini S, Amador XF, Dell'Osso L, et al. Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide. Int Clin Psychopharmacol. 2003;18:15-21.
27. Trivedi MH, Rush AJ, Carmody TJ, et al. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J Clin Psychiatry. 2001;62:776-781.
28. Nutt DJ. Efficacy of mirtazapine in clinically relevant subgroups of depressed patients. Depress Anxiety. 1998;7:7-10.
29. Silverstone PH, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety. J Clin Psychiatry. 2001;62:523-529.
30. Davidson JR, Meoni P, Haudiquet V, et al. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety. 2002;16:4-13.
31. Furukawa TA, Streiner DL, Young LT, Konoshita Y. Antidepressants plus benzodiazepines for major depression. Cochrane Database Syst Rev. 2001;(3):CD001026.
32. Kapczinski F, Lima MS, Souza JS, et al. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev. 2003;(2):CD003592.